Abnormal accumulation of β-catenin is considered to be a strong driving force in hepatocellular carcinogenesis; however, the mechanism of β-catenin accumulation in tumours is unclear. Here, it was demonstrated that hepatitis B virus X protein (HBx) differentially regulates the level of β-catenin through two ubiquitin-dependent proteasome pathways depending on p53 status. In the presence of p53, HBx downregulated β-catenin through the activation of a p53–Siah-1 proteasome pathway. For this purpose, HBx upregulated Siah-1 expression at the transcriptional level via activation of p53. In the absence of p53, however, HBx stabilized β-catenin through the inhibition of a glycogen synthase kinase-3β-dependent pathway. Interestingly, HBx variants with a Pro-101 to Ser substitution were unable to activate p53 and thus could stabilize β-catenin irrespective of p53 status. Based on these findings, a model of β-catenin regulation by HBx is proposed whereby the balance between the two opposite activities of HBx determines the overall expression level of β-catenin. Differential regulation of β-catenin by HBx depending on host (p53 status) and viral factors (HBx sequence variation) helps not only to explain the observation that cancers accumulating β-catenin also exhibit a high frequency of p53 mutations but also to understand the contradictory reports on the roles of HBx during hepatocellular carcinogenesis.
AhnJ. Y.,
ChungE. Y.,
KwunH. J.,
LeeC. W.,
SungY. C.,
JangK. L.2002; Dual effects of hepatitis B virus X protein on the regulation of cell-cycle control depending on the status of cellular p53. J Gen Virol 83:2765–2772
BennJ.,
SuF.,
DoriaM.,
SchneiderR. J.1996; Hepatitis B virus HBx protein induces transcription factor AP-1 by activation of extracellular signal-regulated and c-Jun N-terminal mitogen-activated protein kinases. J Virol 70:4978–4985
CalenderA.,
BillaudM.,
AubryJ. P.,
BanchereauJ.,
VuillaumeM.,
LenoirG. M.1987; Epstein–Barr virus (EBV) induces expression of B-cell activation markers on in vitro infection of EBV-negative B-lymphoma cells. Proc Natl Acad Sci U S A 84:8060–8064[CrossRef]
ChaM. Y.,
KimC. M.,
ParkY. M.,
RyuW. S.2004; Hepatitis B virus X protein is essential for the activation of Wnt/ β -catenin signaling in hepatoma cells. Hepatology 39:1683–1693[CrossRef]
ColnotS.,
DecaensT.,
Niwa-KawakitaM.,
GodardC.,
HamardG.,
KahnA.,
GiovanniniM.,
PerretC.2004; Liver-targeted disruption of Apc in mice activates β -catenin signaling and leads to hepatocellular carcinomas. Proc Natl Acad Sci U S A 101:17216–17221[CrossRef]
de La CosteA.,
RomagnoloB.,
BilluartP.,
RenardC. A.,
BuendiaM. A.,
SoubraneO.,
FabreM.,
ChellyJ.,
BeldjordC.other authors1998; Somatic mutations of the β -catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A 95:8847–8851[CrossRef]
DevereuxT. R.,
SternM. C.,
FlakeG. P.,
YuM. C.,
ZhangZ. Q.,
LondonS. J.,
TaylorJ. A.2001; CTNNB1 mutations and β -catenin protein accumulation in human hepatocellular carcinomas associated with high exposure to aflatoxin B1. Mol Carcinog 31:68–73[CrossRef]
ElmoreL. W.,
HancockA. R.,
ChangS. F.,
WangX. W.,
ChangS.,
CallahanC. P.,
GellerD. A.,
WillH.,
HarrisC. C.1997; Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc Natl Acad Sci U S A 94:14707–14712[CrossRef]
FiucciG.,
BeaucourtS.,
DuflautD.,
LespagnolA.,
Stumptner-CuveletteP.,
GeantA.,
BuchwalterG.,
TuynderM.,
SusiniL.other authors2004; Siah-1b is a direct transcriptional target of p53: identification of the functional p53 responsive element in the siah-1b promoter. Proc Natl Acad Sci U S A 101:3510–3515[CrossRef]
HeT. C.,
SparksA. B.,
RagoC.,
HermekingH.,
ZawelL.,
da CostaL. T.,
MorinP. J.,
VogelsteinB.,
KinzlerK. W.1998; Identification of c-MYC as a target of the APC pathway. Science 281:1509–1512[CrossRef]
HuG.,
FearonE. R.1999; Siah-1 N-terminal RING domain is required for proteolysis function, and C-terminal sequences regulate oligomerization and binding to target proteins. Mol Cell Biol 19:724–732
IwaiA.,
MarusawaH.,
MatsuzawaS.,
FukushimaT.,
HijikataM.,
ReedJ. C.,
ShimotohnoK.,
ChibaT.2004; Siah-1L, a novel transcript variant belonging to the human Siah family of proteins, regulates β -catenin activity in a p53-dependent manner. Oncogene 23:7593–7600[CrossRef]
JangK. L.,
ShackelfordJ.,
SeoS. Y.,
PaganoJ. S.2005; Up-regulation of β -catenin by a viral oncogene correlates with inhibition of the seven in absentia homolog 1 in B lymphoma cells. Proc Natl Acad Sci U S A 102:18431–18436[CrossRef]
JanusF.,
AlbrechtsenN.,
KnippschildU.,
WiesmullerL.,
GrosseF.,
DeppertW.1999; Different regulation of the p53 core domain activities 3′-to-5′ exonuclease and sequence-specific DNA binding. Mol Cell Biol 19:2155–2168
KatohH.,
ShibataT.,
KokubuA.,
OjimaH.,
KosugeT.,
KanaiY.,
HirohashiS.2006; Genetic inactivation of the APC gene contributes to the malignant progression of sporadic hepatocellular carcinoma: a case report. Genes Chromosomes Cancer 45:1050–1057[CrossRef]
KwunH. J.,
JangK. L.2004; Natural variants of hepatitis B virus X protein have differential effects on the expression of cyclin-dependent kinase inhibitor p21 gene. Nucleic Acids Res 32:2202–2213[CrossRef]
LeeC. W.,
SorensenT. S.,
ShikamaN.,
La ThangueN. B.1998; Functional interplay between p53 and E2F through co-activator p300. Oncogene 16:2695–2710[CrossRef]
MaguireH. F.,
HoefflerJ. P.,
SiddiquiA.1991; HBV X protein alters the DNA binding specificity of CREB and ATF-2 by protein–protein interactions. Science 252:842–844[CrossRef]
MatsuzawaS. I.,
ReedJ. C.2001; Siah-1, SIP, and Ebi collaborate in a novel pathway for β -catenin degradation linked to p53 responses. Mol Cell 7:915–926[CrossRef]
MorganS. E.,
KimR.,
WangP. C.,
BhatU. G.,
KusumotoH.,
LuT.,
BeckW. T.2000; Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells. Oncogene 19:5010–5019[CrossRef]
ParkU. S.,
ParkS. K.,
LeeY. I.,
ParkJ. G.,
LeeY. I.2000; Hepatitis B virus-X protein upregulates the expression of p21waf1/cip1 and prolongs G1 to S transition via a p53-independent pathway in human hepatoma cells. Oncogene 19:3384–3394[CrossRef]
PaterliniP.,
PoussinK.,
KewM.,
FrancoD.,
BrechotC.1995; Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma. Hepatology 21:313–321
ProstS.,
FordJ. M.,
TaylorC.,
DoigJ.,
HarrisonD. J.1998; Hepatitis B x protein inhibits p53-dependent DNA repair in primary mouse hepatocytes. J Biol Chem 273:33327–33332[CrossRef]
QadriI.,
MaguireH. F.,
SiddiquiA.1995; Hepatitis B virus transactivator protein X interacts with the TATA-binding protein. Proc Natl Acad Sci U S A 92:1003–1007[CrossRef]
SatohS.,
DaigoY.,
FurukawaY.,
KatoT.,
MiwaN.,
NishiwakiT.,
KawasoeT.,
IshiguroH.,
FujitaM.other authors2000; AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 24:245–250[CrossRef]
ShihW. L.,
KuoM. L.,
ChuangS. E.,
ChengA. L.,
DoongS. L.2000; Hepatitis B virus X protein inhibits transforming growth factor- β -induced apoptosis through the activation of phosphatidylinositol 3-kinase pathway. J Biol Chem 275:25858–25864[CrossRef]
SlagleB. L.,
LeeT. H.,
MedinaD.,
FinegoldM. J.,
ButelJ. S.1996; Increased sensitivity to the hepatocarcinogen diethylnitrosamine in transgenic mice carrying the hepatitis B virus X gene. Mol Carcinog 15:261–269[CrossRef]
SohnS.,
Jaitovitch-GroismanI.,
BenlimameN.,
GalipeauJ.,
BatistG.,
Alaoui-JamaliM. A.2000; Retroviral expression of the hepatitis B virus x gene promotes liver cell susceptibility to carcinogen-induced site specific mutagenesis. Mutat Res 460:17–28[CrossRef]
TaniguchiK.,
RobertsL. R.,
AdercaI. N.,
DongX.,
QianC.,
MurphyL. M.,
NagorneyD. M.,
BurgartL. J.,
RocheP. C.other authors2002; Mutational spectrum of β -catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 21:4863–4871[CrossRef]
TerradillosO.,
BilletO.,
RenardC. A.,
LevyR.,
MolinaT.,
BriandP.,
BuendiaM. A.1997; The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice. Oncogene 14:395–404[CrossRef]
van de WeteringM.,
OosterwegelM.,
DooijesD.,
CleversH.1991; Identification and cloning of TCF-1, a T lymphocyte-specific transcription factor containing a sequence-specific HMG box. EMBO J 10:123–132
WongC. M.,
FanS. T.,
NgI. O.2001; β -Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer 92:136–145[CrossRef]